Experimental 'Natural Killer' cell therapy takes on tough blood cancers
NCT ID NCT05020678
First seen Apr 21, 2026 · Last updated May 04, 2026 · Updated 3 times
Summary
This early-phase study tests an experimental therapy called NKX019, made from donor immune cells (natural killer cells) engineered to target and kill cancer cells. It is for people with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to other treatments. The main goals are to check safety and see if the therapy shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
Institute of Haematology, Royal Prince Alfred Hospital
Camperdown, New South Wales, 2050, Australia
-
Peter MacCallum Cancer Center
Melbourne, Victoria, 3000, Australia
-
Royal Brisbane and Woman's Hospital
Brisbane, Queensland, 4029, Australia
-
St. Vincent's Hospital
Sydney, New South Wales, 2010, Australia
-
The Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
Conditions
Explore the condition pages connected to this study.